TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Engelhardt, Monika
AU  - Leleu, Xavier
AU  - Gironella Mesa, Mercedes
AU  - Cavo, Michele
AU  - Dimopoulos, Meletios Athanasios
AU  - Bianco, Martina
AU  - Marino Merlo, Giovanni
AU  - la Porte, Charles
AU  - Richardson, Paul G.
AU  - Moreau, Philippe
PY  - 2024
SN  - 0902-4441
UR  - http://hdl.handle.net/10366/166736
AB  - [EN] Objectives: To analyze the impact of prior therapies on outcomes with selinexor, bortezomib,
and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in
402 patients with relapsed/refractory multiple myeloma (RRMM) in the phase 3...
LA  - eng
PB  - Wiley
KW  - Bortezomib
KW  - Follow-up studies
KW  - Lenalidomide
KW  - Multiple myeloma
KW  - Proteasome inhibitor
KW  - Selinexor
KW  - Multiple Myeloma
KW  - Dexamethasone
TI  - Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial
DO  - 10.1111/ejh.14223
T2  - European Journal of Haematology
VL  - 113
M2  - 242
ER  -